WO2004004634A3 - Traitement de l'infecondite par l'exemestane - Google Patents

Traitement de l'infecondite par l'exemestane Download PDF

Info

Publication number
WO2004004634A3
WO2004004634A3 PCT/US2003/016252 US0316252W WO2004004634A3 WO 2004004634 A3 WO2004004634 A3 WO 2004004634A3 US 0316252 W US0316252 W US 0316252W WO 2004004634 A3 WO2004004634 A3 WO 2004004634A3
Authority
WO
WIPO (PCT)
Prior art keywords
exemestane
infertility treatment
infertility
treatment
administration
Prior art date
Application number
PCT/US2003/016252
Other languages
English (en)
Other versions
WO2004004634A2 (fr
Inventor
Charles P Wajszczuk
Gans Hendrik J Dekoning
Original Assignee
Pharmacia Italia Spa
Charles P Wajszczuk
Gans Hendrik J Dekoning
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Charles P Wajszczuk, Gans Hendrik J Dekoning filed Critical Pharmacia Italia Spa
Priority to CA002491372A priority Critical patent/CA2491372A1/fr
Priority to JP2004519563A priority patent/JP2005536490A/ja
Priority to AU2003247404A priority patent/AU2003247404A1/en
Priority to EP03762980A priority patent/EP1531829A2/fr
Priority to MXPA05000251A priority patent/MXPA05000251A/es
Priority to BR0312393-6A priority patent/BR0312393A/pt
Publication of WO2004004634A2 publication Critical patent/WO2004004634A2/fr
Publication of WO2004004634A3 publication Critical patent/WO2004004634A3/fr
Priority to IL16581304A priority patent/IL165813A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé thérapeutique permettant de traiter l'infécondité chez un hôte femelle, qui consiste à lui administrer une dose efficace d'exémestane de stimulation folliculaire ovarienne.
PCT/US2003/016252 2002-07-02 2003-07-02 Traitement de l'infecondite par l'exemestane WO2004004634A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002491372A CA2491372A1 (fr) 2002-07-02 2003-07-02 Traitement de l'infecondite par l'exemestane
JP2004519563A JP2005536490A (ja) 2002-07-02 2003-07-02 エキセメスタンによる不妊症治療
AU2003247404A AU2003247404A1 (en) 2002-07-02 2003-07-02 Infertility treatment with exemestane
EP03762980A EP1531829A2 (fr) 2002-07-02 2003-07-02 Traitement de l'infecondite par l'exemestane
MXPA05000251A MXPA05000251A (es) 2002-07-02 2003-07-02 Tratamiento de la infertilidad con exemestano.
BR0312393-6A BR0312393A (pt) 2002-07-02 2003-07-02 Tratamento de infertilidade com exemestano
IL16581304A IL165813A0 (en) 2002-07-02 2004-12-16 Infertility treatment with exemestane

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39332002P 2002-07-02 2002-07-02
US60/393,320 2002-07-02

Publications (2)

Publication Number Publication Date
WO2004004634A2 WO2004004634A2 (fr) 2004-01-15
WO2004004634A3 true WO2004004634A3 (fr) 2004-04-08

Family

ID=30115565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016252 WO2004004634A2 (fr) 2002-07-02 2003-07-02 Traitement de l'infecondite par l'exemestane

Country Status (12)

Country Link
EP (1) EP1531829A2 (fr)
JP (1) JP2005536490A (fr)
KR (1) KR20050077045A (fr)
CN (1) CN1665516A (fr)
AU (1) AU2003247404A1 (fr)
BR (1) BR0312393A (fr)
CA (1) CA2491372A1 (fr)
IL (1) IL165813A0 (fr)
MX (1) MXPA05000251A (fr)
PL (1) PL373219A1 (fr)
WO (1) WO2004004634A2 (fr)
ZA (1) ZA200410135B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102432156B1 (ko) * 2020-05-18 2022-08-11 제주대학교 산학협력단 화학물질을 포함하는 어류의 성 성숙 제어용 조성물 및 이를 이용한 어류의 성 성숙 제어방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311599T3 (es) * 2001-04-17 2009-02-16 Ares Trading S.A. Dosis unica de inhibidores de la aromatasa para tratar la infertilidad.
PL366554A1 (en) * 2001-04-17 2005-02-07 Ares Trading S.A. Aromatase inhibition to enhance assisted reproduction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS GIUDICHI ET AL.: "6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a nw irreversible aromatase inhibitor", XP002973714, Database accession no. 1988:467168 *
JOURNAL OF STEROID BIOCHEMISTRY, vol. 30, no. 1-6, 1988, pages 391 - 394 *

Also Published As

Publication number Publication date
MXPA05000251A (es) 2005-07-15
BR0312393A (pt) 2005-04-12
CA2491372A1 (fr) 2004-01-15
ZA200410135B (en) 2006-07-26
AU2003247404A1 (en) 2004-01-23
EP1531829A2 (fr) 2005-05-25
CN1665516A (zh) 2005-09-07
JP2005536490A (ja) 2005-12-02
IL165813A0 (en) 2006-01-15
KR20050077045A (ko) 2005-07-29
WO2004004634A2 (fr) 2004-01-15
PL373219A1 (en) 2005-08-22

Similar Documents

Publication Publication Date Title
WO2004037205A3 (fr) THERAPIES FAIBLEMENT DOSEES POUR TRAITER DES TROUBLES POUR LESQUELS L'ACTIVITE DES FACTEURS DE NECROSE TUMORALE α EST PREJUDICIABLE
AU2003213771A1 (en) Method for modification of radiotherapy treatment delivery
WO2005000213A8 (fr) Methode permettant de traiter des maladies a l'aide d'agent d'inhibition hsp90 combines a des inhibiteurs d'enzymes
WO2004009776A3 (fr) Traitement de troubles en relation avec le tnf$g(a)
WO2004010937A3 (fr) Methode de traitement du cancer
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
WO2003082260A3 (fr) Traitement de la tuberculose
AU2003201868A1 (en) Aqueous agent for treating substrate, method for treating substrate and treated substrate
EP1628667A4 (fr) Methode permettant de traiter des maladies a l'aide d'agents d'inhibition hsp90 combines a des antimitotiques
WO2004108080A3 (fr) Procede pour traiter des maladies au moyen d'agents inhibiteurs de hsp90 en combinaison avec des agents immunosuppresseurs
WO2005002506A3 (fr) Methode de traitement de maladies mettant en oeuvre des agents inhibant hsp90 conjointement avec des antimetabolites
WO2005000212A3 (fr) Procede de traitement de maladies par des agents inhibiteurs de hsp90 en combinaison avec des inhibiteurs d'exportation nucleaire
AU2000258352A1 (en) Acupuncture points stimulation for treating various diseases
WO2004071413A3 (fr) Procede et composition pour potentialiser un analgesique opiace
WO2004004634A3 (fr) Traitement de l'infecondite par l'exemestane
AU2003239813A1 (en) Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori
WO2003094957A3 (fr) Methodes de therapie
IL151926A0 (en) Drug for stimulating leucopoiesis and for treating tumour diseases, protozoal diseases, acariasis and arthropodiasis, and process for producing it
PL367401A1 (en) Utilization of buprenorphine in urinary incontinence therapy
AU2003245517A1 (en) Apparatus and method for physiological treatment with electromagnetic energy
WO2004105698A3 (fr) Utilisation d'inhibiteurs de phosphatase en tant que traitement d'appoint pour troubles psychiatriques
AU2003242991A1 (en) Apparatus for therapeutic treatments
UA70019A (en) Method for treating nasal furuncles
WO2002066037A3 (fr) Methode d'utilisation antivirale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004/10135

Country of ref document: ZA

Ref document number: 200410135

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 165813

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 537404

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004519563

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2491372

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/000251

Country of ref document: MX

Ref document number: 373219

Country of ref document: PL

Ref document number: 1020057000051

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038157306

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003762980

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003247404

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500014

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 2003762980

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057000051

Country of ref document: KR